Gene Therapy for Non Ketotic Hyperglycinemia, NKH
In 2019, the Drake Rayden Foundation partnered with the Steven Gray Lab at the University of Texas Southwestern, UTSW for a two year project to create a gene therapy project for the terminal, rare disease NonKetotic Hyperglycinemia, or Glycine Encephalopathy. The project is lead by Steven Gray, Ph.D, associate professor and expert in AAV gene therapy in the department of Pediatrics, Eugene McDermott Center for Human Growth and Development. Dr. Gray has pioneered gene therapy treatments for various neurological diseases. At UT Southwestern he is overseeing one of the nation’s few facilities that manufactures a special type of gene-delivering virus for patient use.
Watch the inspiring video of UTSW and their cutting edge gene therapy techniques helping families suffering terminal illnesses.
NKH Patient or Support Group
Would you like to stay up to date on our latest advancements and clinical trial registries for Non Ketotic Hyperglycinemia?
Sign up to receive research updates specifically designed with NKH families in mind.
You will get updates pertaining advancing research, potential therapies, and new updates on how to get involved with up and coming research.
Someone from our team
will be in touch very soon
once you have submitted the
If you have any questions please
feel free to reach out to
The Drake Rayden Foundation funded
$67,000.00 for NKH Research
at the University of Notre Dame,
Boler-Parseghian Center for Rare and Neglected Diseases
Tarah O’Sullivan, representing the
Drake Rayden Foundation
Was a guest speaker at the 10th Annual Conference on Advancing Rare Disease Research, Therapy, and Patient Advocacy.
The Drake Rayden Foundation had the opportunity to have individual meetings with all three major researchers in the world. We discussed research, the potential direction, and funding needed to obtain their vision.